Constitutively overexpressed erythropoietin reduces infarct size in a mouse model of permanent coronary artery ligation.
In view of the emerging role of recombinant human erythropoietin (rhEPO) as a novel therapeutical approach in myocardial ischemia, we performed the first two-way parallel comparison to test the effects of rhEPO pretreatment (1000 U/kg, 12h before surgery) versus EPO transgenic overexpression in a mouse model of myocardial infarction. Unlike EPO transgenic mice who doubled their hematocrit, rhEPO pretreated mice maintained an unaltered hematocrit, thereby offering the possibility to discern erythropoietic-dependent from erythropoietic-independent protective effects of EPO. Animals pretreated with rhEPO as well as EPO transgenic mice underwent permanent left anterior descending (LAD) coronary artery ligation. Resulting infarct size was determined 24h after LAD ligation by hematoxylin/eosin staining, and morphometrical analysis was performed by computerized planimetry. A large reduction in infarction size was observed in rhEPO-treated mice (-74% +/- 14.51; P = 0.0002) and an even more pronounced reduction in the EPO transgenic group (-87% +/- 6.31; P < 0.0001) when compared to wild-type controls. Moreover, while searching for novel early ischemic markers, we analyzed expression of hypoxia-sensitive Wilms' tumor suppressor gene (WT1) in infarcted hearts. We found that its expression correlated with the infarct area, thereby providing the first demonstration that WT1 is a useful early marker of myocardial infarction. This study demonstrates for the first time that, despite high hematocrit levels, endogenously overexpressed EPO provides protection against myocardial infarction in a murine model of permanent LAD ligation.
Camici
Giovanni G
GG
Cardiology and Cardiovascular Research and Institute of Physiology, University of Zürich, Zürich, Switzerland.
Stallmach
Thomas
T
Hermann
Matthias
M
Hassink
Rutger
R
Doevendans
Peter
P
Grenacher
Beat
B
Hirschy
Alain
A
Vogel
Johannes
J
Lüscher
Thomas F
TF
Ruschitzka
Frank
F
Gassmann
Max
M
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D003331:Coronary Vessels; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000097:blood / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D006400:Hematocrit; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009203:Myocardial Infarction / Q000235:genetics / Q000473:pathology* / Q000517:prevention & control*; D011994:Recombinant Proteins; D025721:WT1 Proteins / Q000032:analysis*
D015415:Biomarkers; D011994:Recombinant Proteins; D025721:WT1 Proteins; D004921:Erythropoietin